Review
Nature Reviews Drug Discovery 1, 867-881 (November 2002) | doi:10.1038/nrd937
Hepatitis C therapeutics: current status and emerging strategies
Seng-Lai Tan1, Arnim Pause2, Yuguang Shi3 & Nahum Sonenberg2 About the authors
Abstract
Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite these obstacles, inhibitors of the replicative elements of HCV, immune modulators and non-specific hepatoprotective agents are being pursued and exciting progress has been made. Successful therapeutic intervention of HCV will probably require combination approaches and new approaches, including host drug discovery targets.
- View At a Glance
Author affiliations
- Infectious Diseases Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
- Endocrine Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
- Department of Biochemistry and McGill Cancer Centre, McGill University, 3655 Drummond Street, Montreal, Quebec, Canada H3G 1Y6.
Correspondence to: Nahum Sonenberg2 Email: nahum.sonenberg@mcgill.ca
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE RESEARCH |
